Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Circular RNAs as a novel layer of regulatory mechanism in multiple sclerosis.

Zurawska A, Mycko MP, Selmaj KW.

J Neuroimmunol. 2019 May 25;334:576971. doi: 10.1016/j.jneuroim.2019.576971. [Epub ahead of print] Review.

PMID:
31163273
2.

Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management.

Cuker A, Bass AD, Nadj C, Agius MA, Steingo B, Selmaj KW, Thoits T, Guerreiro A, Van Wijmeersch B, Ziemssen T, Meuth SG, LaGanke CC, Thangavelu K, Rodriguez CE, Baker DP, Margolin DH, Jannsens A.

Mult Scler. 2019 Feb 20:1352458518816612. doi: 10.1177/1352458518816612. [Epub ahead of print]

PMID:
30785358
3.

Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study.

Wray S, Havrdova E, Snydman DR, Arnold DL, Cohen JA, Coles AJ, Hartung HP, Selmaj KW, Weiner HL, Daizadeh N, Margolin DH, Chirieac MC, Compston DAS.

Mult Scler. 2018 Oct 5:1352458518796675. doi: 10.1177/1352458518796675. [Epub ahead of print]

PMID:
30289355
4.

Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.

Cohen JA, Comi G, Arnold DL, Bar-Or A, Selmaj KW, Steinman L, Havrdová EK, Cree BA, Montalbán X, Hartung HP, Huang V, Frohna P, Skolnick BE, Kappos L; RADIANCE Trial Investigators.

Mult Scler. 2018 Jul 25:1352458518789884. doi: 10.1177/1352458518789884. [Epub ahead of print]

PMID:
30043658
5.

Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis.

Rose JW, Giovannoni G, Wiendl H, Gold R, Havrdová E, Kappos L, Selmaj KW, Zhao J, Riester K, Tsao LC, Greenberg SJ.

Mult Scler Relat Disord. 2017 Oct;17:32-40. doi: 10.1016/j.msard.2017.06.006. Epub 2017 Jun 19.

PMID:
29055471
6.

Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.

Coles AJ, Cohen JA, Fox EJ, Giovannoni G, Hartung HP, Havrdova E, Schippling S, Selmaj KW, Traboulsee A, Compston DAS, Margolin DH, Thangavelu K, Chirieac MC, Jody D, Xenopoulos P, Hogan RJ, Panzara MA, Arnold DL; CARE-MS II and CAMMS03409 Investigators.

Neurology. 2017 Sep 12;89(11):1117-1126. doi: 10.1212/WNL.0000000000004354. Epub 2017 Aug 23.

7.

Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy.

Havrdova E, Arnold DL, Cohen JA, Hartung HP, Fox EJ, Giovannoni G, Schippling S, Selmaj KW, Traboulsee A, Compston DAS, Margolin DH, Thangavelu K, Rodriguez CE, Jody D, Hogan RJ, Xenopoulos P, Panzara MA, Coles AJ; CARE-MS I and CAMMS03409 Investigators.

Neurology. 2017 Sep 12;89(11):1107-1116. doi: 10.1212/WNL.0000000000004313. Epub 2017 Aug 23. Erratum in: Neurology. 2018 Apr 17;90(16):755.

8.

Multiple sclerosis: Skin-induced antigen-specific immune tolerance.

Wildner P, Selmaj KW.

J Neuroimmunol. 2017 Oct 15;311:49-58. doi: 10.1016/j.jneuroim.2017.08.001. Epub 2017 Aug 2. Review.

PMID:
28803660
9.

Global exosome transcriptome profiling reveals biomarkers for multiple sclerosis.

Selmaj I, Cichalewska M, Namiecinska M, Galazka G, Horzelski W, Selmaj KW, Mycko MP.

Ann Neurol. 2017 May;81(5):703-717. doi: 10.1002/ana.24931.

PMID:
28411393
10.

The role of exosomes in CNS inflammation and their involvement in multiple sclerosis.

Selmaj I, Mycko MP, Raine CS, Selmaj KW.

J Neuroimmunol. 2017 May 15;306:1-10. doi: 10.1016/j.jneuroim.2017.02.002. Epub 2017 Feb 6. Review.

PMID:
28385180
11.

Multiple sclerosis: Serum-derived exosomes express myelin proteins.

Galazka G, Mycko MP, Selmaj I, Raine CS, Selmaj KW.

Mult Scler. 2018 Apr;24(4):449-458. doi: 10.1177/1352458517696597. Epub 2017 Feb 1.

PMID:
28273783
12.

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.

Giovannoni G, Cohen JA, Coles AJ, Hartung HP, Havrdova E, Selmaj KW, Margolin DH, Lake SL, Kaup SM, Panzara MA, Compston DA; CARE-MS II Investigators.

Neurology. 2016 Nov 8;87(19):1985-1992. Epub 2016 Oct 12.

13.

Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS.

Arnold DL, Fisher E, Brinar VV, Cohen JA, Coles AJ, Giovannoni G, Hartung HP, Havrdova E, Selmaj KW, Stojanovic M, Weiner HL, Lake SL, Margolin DH, Thomas DR, Panzara MA, Compston DA; CARE-MS I and CARE-MS II Investigators.

Neurology. 2016 Oct 4;87(14):1464-1472. Epub 2016 Sep 2.

14.

Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial.

Cohen JA, Arnold DL, Comi G, Bar-Or A, Gujrathi S, Hartung JP, Cravets M, Olson A, Frohna PA, Selmaj KW; RADIANCE Study Group.

Lancet Neurol. 2016 Apr;15(4):373-81. doi: 10.1016/S1474-4422(16)00018-1. Epub 2016 Feb 12.

PMID:
26879276
15.

miR-155-3p Drives the Development of Autoimmune Demyelination by Regulation of Heat Shock Protein 40.

Mycko MP, Cichalewska M, Cwiklinska H, Selmaj KW.

J Neurosci. 2015 Dec 16;35(50):16504-15. doi: 10.1523/JNEUROSCI.2830-15.2015.

16.

Heat shock protein 70 (Hsp70) interacts with the Notch1 intracellular domain and contributes to the activity of Notch signaling in myelin-reactive CD4 T cells.

Juryńczyk M, Lewkowicz P, Domowicz M, Mycko MP, Selmaj KW.

J Neuroimmunol. 2015 Oct 15;287:19-26. doi: 10.1016/j.jneuroim.2015.08.007. Epub 2015 Aug 8.

PMID:
26439956
17.

Dysregulated RNA-Induced Silencing Complex (RISC) Assembly within CNS Corresponds with Abnormal miRNA Expression during Autoimmune Demyelination.

Lewkowicz P, Cwiklińska H, Mycko MP, Cichalewska M, Domowicz M, Lewkowicz N, Jurewicz A, Selmaj KW.

J Neurosci. 2015 May 13;35(19):7521-37. doi: 10.1523/JNEUROSCI.4794-14.2015.

18.

Brain glycolipids suppress T helper cells and inhibit autoimmune demyelination.

Mycko MP, Sliwinska B, Cichalewska M, Cwiklinska H, Raine CS, Selmaj KW.

J Neurosci. 2014 Jun 18;34(25):8646-58. doi: 10.1523/JNEUROSCI.0885-14.2014.

19.

Plasmocytoid dendritic cell deficit of early response to toll-like receptor 7 agonist stimulation in multiple sclerosis patients.

Mycko MP, Cwiklinska H, Cichalewska M, Matysiak M, Lewkowicz P, Sliwinska B, Selmaj I, Selmaj KW.

Clin Immunol. 2014 Jul;153(1):211-9. doi: 10.1016/j.clim.2014.04.016. Epub 2014 May 9.

PMID:
24814238
20.
21.

A "candidate-interactome" aggregate analysis of genome-wide association data in multiple sclerosis.

Mechelli R, Umeton R, Policano C, Annibali V, Coarelli G, Ricigliano VA, Vittori D, Fornasiero A, Buscarinu MC; International Multiple Sclerosis Genetics Consortium; Wellcome Trust Case Control Consortium,2, Romano S, Salvetti M, Ristori G.

PLoS One. 2013 May 16;8(5):e63300. doi: 10.1371/journal.pone.0063300. Print 2013.

22.

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.

Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DA; CARE-MS I investigators.

Lancet. 2012 Nov 24;380(9856):1819-28. doi: 10.1016/S0140-6736(12)61769-3. Epub 2012 Nov 1.

PMID:
23122652
23.

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.

Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA; CARE-MS II investigators.

Lancet. 2012 Nov 24;380(9856):1829-39. doi: 10.1016/S0140-6736(12)61768-1. Epub 2012 Nov 1.

PMID:
23122650
24.

Transcriptional profiling of microdissected areas of active multiple sclerosis lesions reveals activation of heat shock protein genes.

Mycko MP, Brosnan CF, Raine CS, Fendler W, Selmaj KW.

J Neurosci Res. 2012 Oct;90(10):1941-8. doi: 10.1002/jnr.23079. Epub 2012 Jun 20.

PMID:
22715030
25.

MicroRNA-301a regulation of a T-helper 17 immune response controls autoimmune demyelination.

Mycko MP, Cichalewska M, Machlanska A, Cwiklinska H, Mariasiewicz M, Selmaj KW.

Proc Natl Acad Sci U S A. 2012 May 15;109(20):E1248-57. doi: 10.1073/pnas.1114325109. Epub 2012 Apr 18.

26.

Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial.

Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, Skoromets A, Stolyarov I, Bass A, Sullivan H, Margolin DH, Lake SL, Moran S, Palmer J, Smith MS, Compston DA.

Neurology. 2012 Apr 3;78(14):1069-78. doi: 10.1212/WNL.0b013e31824e8ee7. Epub 2012 Mar 21.

PMID:
22442431
27.

Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis.

International Multiple Sclerosis Genetics Consortium; Wellcome Trust Case Control Consortium 2, Sawcer S, Hellenthal G, Pirinen M, Spencer CC, Patsopoulos NA, Moutsianas L, Dilthey A, Su Z, Freeman C, Hunt SE, Edkins S, Gray E, Booth DR, Potter SC, Goris A, Band G, Oturai AB, Strange A, Saarela J, Bellenguez C, Fontaine B, Gillman M, Hemmer B, Gwilliam R, Zipp F, Jayakumar A, Martin R, Leslie S, Hawkins S, Giannoulatou E, D'alfonso S, Blackburn H, Martinelli Boneschi F, Liddle J, Harbo HF, Perez ML, Spurkland A, Waller MJ, Mycko MP, Ricketts M, Comabella M, Hammond N, Kockum I, McCann OT, Ban M, Whittaker P, Kemppinen A, Weston P, Hawkins C, Widaa S, Zajicek J, Dronov S, Robertson N, Bumpstead SJ, Barcellos LF, Ravindrarajah R, Abraham R, Alfredsson L, Ardlie K, Aubin C, Baker A, Baker K, Baranzini SE, Bergamaschi L, Bergamaschi R, Bernstein A, Berthele A, Boggild M, Bradfield JP, Brassat D, Broadley SA, Buck D, Butzkueven H, Capra R, Carroll WM, Cavalla P, Celius EG, Cepok S, Chiavacci R, Clerget-Darpoux F, Clysters K, Comi G, Cossburn M, Cournu-Rebeix I, Cox MB, Cozen W, Cree BA, Cross AH, Cusi D, Daly MJ, Davis E, de Bakker PI, Debouverie M, D'hooghe MB, Dixon K, Dobosi R, Dubois B, Ellinghaus D, Elovaara I, Esposito F, Fontenille C, Foote S, Franke A, Galimberti D, Ghezzi A, Glessner J, Gomez R, Gout O, Graham C, Grant SF, Guerini FR, Hakonarson H, Hall P, Hamsten A, Hartung HP, Heard RN, Heath S, Hobart J, Hoshi M, Infante-Duarte C, Ingram G, Ingram W, Islam T, Jagodic M, Kabesch M, Kermode AG, Kilpatrick TJ, Kim C, Klopp N, Koivisto K, Larsson M, Lathrop M, Lechner-Scott JS, Leone MA, Leppä V, Liljedahl U, Bomfim IL, Lincoln RR, Link J, Liu J, Lorentzen AR, Lupoli S, Macciardi F, Mack T, Marriott M, Martinelli V, Mason D, McCauley JL, Mentch F, Mero IL, Mihalova T, Montalban X, Mottershead J, Myhr KM, Naldi P, Ollier W, Page A, Palotie A, Pelletier J, Piccio L, Pickersgill T, Piehl F, Pobywajlo S, Quach HL, Ramsay PP, Reunanen M, Reynolds R, Rioux JD, Rodegher M, Roesner S, Rubio JP, Rückert IM, Salvetti M, Salvi E, Santaniello A, Schaefer CA, Schreiber S, Schulze C, Scott RJ, Sellebjerg F, Selmaj KW, Sexton D, Shen L, Simms-Acuna B, Skidmore S, Sleiman PM, Smestad C, Sørensen PS, Søndergaard HB, Stankovich J, Strange RC, Sulonen AM, Sundqvist E, Syvänen AC, Taddeo F, Taylor B, Blackwell JM, Tienari P, Bramon E, Tourbah A, Brown MA, Tronczynska E, Casas JP, Tubridy N, Corvin A, Vickery J, Jankowski J, Villoslada P, Markus HS, Wang K, Mathew CG, Wason J, Palmer CN, Wichmann HE, Plomin R, Willoughby E, Rautanen A, Winkelmann J, Wittig M, Trembath RC, Yaouanq J, Viswanathan AC, Zhang H, Wood NW, Zuvich R, Deloukas P, Langford C, Duncanson A, Oksenberg JR, Pericak-Vance MA, Haines JL, Olsson T, Hillert J, Ivinson AJ, De Jager PL, Peltonen L, Stewart GJ, Hafler DA, Hauser SL, McVean G, Donnelly P, Compston A.

Nature. 2011 Aug 10;476(7359):214-9. doi: 10.1038/nature10251.

28.

Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.

Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, Bass AD, Wynn DR, Margolin DH, Lake SL, Moran S, Palmer J, Smith MS, Compston DA.

Lancet Neurol. 2011 Apr;10(4):338-48. doi: 10.1016/S1474-4422(11)70020-5.

PMID:
21397567
29.

Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study.

Comi G, Abramsky O, Arbizu T, Boyko A, Gold R, Havrdová E, Komoly S, Selmaj K, Sharrack B, Filippi M; LAQ/5063 Study Group.

Mult Scler. 2010 Nov;16(11):1360-6. doi: 10.1177/1352458510378127. Epub 2010 Sep 8.

PMID:
20834039
30.

Aberrant stress-induced Hsp70 expression in immune cells in multiple sclerosis.

Cwiklinska H, Mycko MP, Szymanska B, Matysiak M, Selmaj KW.

J Neurosci Res. 2010 Nov 1;88(14):3102-10. doi: 10.1002/jnr.22476.

PMID:
20806409
31.

NCF1 gene and pseudogene pattern: association with parasitic infection and autoimmunity.

Greve B, Hoffmann P, Vonthein R, Kun J, Lell B, Mycko MP, Selmaj KW, Berger K, Weissert R, Kremsner PG.

Malar J. 2008 Dec 11;7:251. doi: 10.1186/1475-2875-7-251.

32.

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

CAMMS223 Trial Investigators, Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, Margolin DH, Norris K, Tandon PK.

N Engl J Med. 2008 Oct 23;359(17):1786-801. doi: 10.1056/NEJMoa0802670.

33.

A heat shock protein gene (Hsp70.1) is critically involved in the generation of the immune response to myelin antigen.

Mycko MP, Cwiklinska H, Walczak A, Libert C, Raine CS, Selmaj KW.

Eur J Immunol. 2008 Jul;38(7):1999-2013. doi: 10.1002/eji.200737661.

34.

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.

Comi G, Pulizzi A, Rovaris M, Abramsky O, Arbizu T, Boiko A, Gold R, Havrdova E, Komoly S, Selmaj K, Sharrack B, Filippi M; LAQ/5062 Study Group.

Lancet. 2008 Jun 21;371(9630):2085-92. doi: 10.1016/S0140-6736(08)60918-6.

PMID:
18572078
35.

Multiple sclerosis and the CTLA4 autoimmunity polymorphism CT60: no association in patients from Germany, Hungary and Poland.

Greve B, Simonenko R, Illes Z, Peterfalvi A, Hamdi N, Mycko MP, Selmaj KW, Rozsa C, Rajczy K, Bauer P, Berger K, Weissert R.

Mult Scler. 2008 Mar;14(2):153-8. Epub 2007 Oct 17.

PMID:
17942509
36.

Brain-derived heat shock protein 70-peptide complexes induce NK cell-dependent tolerance to experimental autoimmune encephalomyelitis.

Galazka G, Stasiolek M, Walczak A, Jurewicz A, Zylicz A, Brosnan CF, Raine CS, Selmaj KW.

J Immunol. 2006 Feb 1;176(3):1588-99.

37.

Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity.

Roxburgh RH, Seaman SR, Masterman T, Hensiek AE, Sawcer SJ, Vukusic S, Achiti I, Confavreux C, Coustans M, le Page E, Edan G, McDonnell GV, Hawkins S, Trojano M, Liguori M, Cocco E, Marrosu MG, Tesser F, Leone MA, Weber A, Zipp F, Miterski B, Epplen JT, Oturai A, Sørensen PS, Celius EG, Lara NT, Montalban X, Villoslada P, Silva AM, Marta M, Leite I, Dubois B, Rubio J, Butzkueven H, Kilpatrick T, Mycko MP, Selmaj KW, Rio ME, Sá M, Salemi G, Savettieri G, Hillert J, Compston DA.

Neurology. 2005 Apr 12;64(7):1144-51.

PMID:
15824338
38.

Proton magnetic resonance spectroscopy of normal appearing white matter in familial and sporadic multiple sclerosis.

Siger-Zajdel M, Selmaj KW.

J Neurol. 2005 Jul;252(7):830-2. Epub 2005 Mar 18.

PMID:
15772740
39.

Gammadelta T cells enhance the expression of experimental autoimmune encephalomyelitis by promoting antigen presentation and IL-12 production.

Odyniec A, Szczepanik M, Mycko MP, Stasiolek M, Raine CS, Selmaj KW.

J Immunol. 2004 Jul 1;173(1):682-94.

40.

Microarray gene expression profiling of chronic active and inactive lesions in multiple sclerosis.

Mycko MP, Papoian R, Boschert U, Raine CS, Selmaj KW.

Clin Neurol Neurosurg. 2004 Jun;106(3):223-9. Review.

PMID:
15177772
41.

Inducible heat shock protein 70 promotes myelin autoantigen presentation by the HLA class II.

Mycko MP, Cwiklinska H, Szymanski J, Szymanska B, Kudla G, Kilianek L, Odyniec A, Brosnan CF, Selmaj KW.

J Immunol. 2004 Jan 1;172(1):202-13.

42.

A whole genome screen for association in Polish multiple sclerosis patients.

Bielecki B, Mycko MP, Tronczyńska E, Bieniek M, Sawcer S, Setakis E, Benediktsson K, Compston A, Selmaj KW.

J Neuroimmunol. 2003 Oct;143(1-2):107-11.

PMID:
14575925
43.

cDNA microarray analysis in multiple sclerosis lesions: detection of genes associated with disease activity.

Mycko MP, Papoian R, Boschert U, Raine CS, Selmaj KW.

Brain. 2003 May;126(Pt 5):1048-57.

PMID:
12690045
44.

Heat shock protein 70 associations with myelin basic protein and proteolipid protein in multiple sclerosis brains.

Cwiklinska H, Mycko MP, Luvsannorov O, Walkowiak B, Brosnan CF, Raine CS, Selmaj KW.

Int Immunol. 2003 Feb;15(2):241-9.

PMID:
12578854
45.
46.

Shedding of TNF receptors in multiple sclerosis patients.

Jurewicz AM, Walczak AK, Selmaj KW.

Neurology. 1999 Oct 22;53(7):1409-14.

PMID:
10534243
47.

Multiple sclerosis: the increased frequency of the ICAM-1 exon 6 gene point mutation genetic type K469.

Mycko MP, Kwinkowski M, Tronczynska E, Szymanska B, Selmaj KW.

Ann Neurol. 1998 Jul;44(1):70-5.

PMID:
9667594
49.

Proliferation of astrocytes in vitro in response to cytokines. A primary role for tumor necrosis factor.

Selmaj KW, Farooq M, Norton WT, Raine CS, Brosnan CF.

J Immunol. 1990 Jan 1;144(1):129-35.

PMID:
2104886
50.

Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro.

Selmaj KW, Raine CS.

Ann Neurol. 1988 Apr;23(4):339-46.

PMID:
3132891

Supplemental Content

Loading ...
Support Center